Nicox Enters Research Collaboration with Re-Vana Therapeutics to Explore Drug Delivery Platform for the Reduction of IOP

Source: Nicox SA

Friday, October 20, 2017 | Glaucoma , Partnerships , Nicox


Nicox SA and Re-Vana Therapeutics announced that they have entered into a research collaboration to explore combining Nicox’s next generation of stand-alone nitric oxide (NO)-donors with Re-Vana's EyeLief long-acting photo-crosslinked biodegradable drug delivery platform for the reduction of IOP.

“Re-Vana's technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO-donors," Michael Bergamini, Nicox’s Executive Vice President and Chief Scientific Officer, said in a company news release. "EyeLief technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP. We look forward to working with Re-Vana on this innovative research endeavor."

"The Nicox team has built a strong dataset demonstrating the role of nitric oxide in the reduction of IOP,” Michael O’Rourke, President & CEO of Re-Vana Therapeutics, said in the news release. "We believe that our biodegradable photo-crosslinked sustained delivery technology, EyeLief, in combination with Nicox’s novel technology, has the potential to serve as an effective therapeutic approach to lowering IOP to prevent the progression and development of glaucoma."

The non-exclusive collaboration will focus on the development of the EyeLief drug delivery platform for sustained release of certain of Nicox’s next generation of stand-alone NO-donors. EyeLief is a novel sustained-release, photo-crosslinked, preformed, biodegradable implant technology intended to release therapeutics over an extended period of time after insertion in the eye.

Under the terms of the agreement, Re-Vana will be responsible for the development and characterization of EyeLief implants containing Nicox’s NO-donors, and subsequently for initial in-vitro evaluation of the implants' sustained-release characteristics over a number of months. New jointly-developed intellectual property from the collaboration relating to these sustained-release formulations will be jointly owned. Depending on the outcome of the research collaboration under this agreement, Nicox and Re-Vana may then enter into discussions regarding the further development of other product candidates. Payments by Nicox associated with this agreement are not considered material to Nicox's financial statements at this time.


Comments

You must be logged in to leave a comment.